ADNEX MR评分系统的外部验证:一项单中心回顾性研究
本研究回顾性纳入2007年1月至2014年12月间663例女性778个超声定性困难的附件肿块,评估ADNEX MR评分系统的诊断准确性。两位放射科医师独立评分,以评分≥4分为恶性。该系统鉴别良恶性的AUC为0.929和0.923,敏感度85.6%和84.6%,特异度91.7%和91.9%,但交界性/低度恶性潜能肿瘤的误分类率较高(46.1%)。
要点
- ADNEX MR评分≥4分判为恶性,两位阅片者AUC分别为0.929和0.923。
- 交界性/低度恶性潜能肿瘤误分类率46.1%,高于其他恶性肿瘤的6-7.4%。
- 评分2、3、4、5分的恶性率随评分升高而递增。
核心结论
- ADNEX MR评分系统鉴别附件肿块良恶性高度准确,但对交界性/低度恶性潜能肿瘤可能准确性较低。
研究设计与样本
- 单中心回顾性研究,纳入663例女性778个超声定性困难的附件肿块(590个良性,188个恶性),两位放射科医师独立阅片并按ADNEX MR评分系统评分1-5分,以评分≥4分为恶性,采用ROC分析评估诊断性能。
关键影像表现/征象
- 评分2、3、4、5分的恶性率:阅片者1为1.9%(8/419)、12.8%(19/149)、62.6%(57/91)、87.4%(104/119);阅片者2为2.1%(9/424)、13.6%(20/147)、67.6%(71/105)、86.3%(88/102)。
诊断标准与关键数值
- 评分≥4分考虑为恶性(包括交界性/低度恶性潜能肿瘤)。
- 阅片者1:AUC 0.929,敏感度85.6%(161/188),特异度91.7%(541/590),准确率90.2%(702/778)。
- 阅片者2:AUC 0.923,敏感度84.6%(159/188),特异度91.9%(542/590),准确率90.1%(701/778)。
- 交界性/低度恶性潜能肿瘤误分类率46.1%,其他恶性肿瘤为6-7.4%。
临床应用与阅片要点
- 对超声定性困难的附件肿块,可按ADNEX MR评分系统评分并以≥4分作为恶性判断阈值。
- 交界性/低度恶性潜能肿瘤误分类率较高(46.1%),阅片时需注意此类病变可能被低估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate the accuracy of the ADNEX MR SCORING system for characterising adnexal masses.
MATERIALS AND METHODS: An institutional review board approved this retrospective study. The study population comprised 663 women who underwent magnetic resonance imaging (MRI) from January 2007 to December 2014 to characterise 778 adnexal masses that were indeterminate under ultrasonography (590 benign and 188 malignant). Two radiologists independently reviewed the MRI images. The masses were scored from 1 to 5 according to the ADNEX MR SCORING system. The diagnostic performance of the system was evaluated by receiver operating characteristic (ROC) analysis. Masses scored 4 or greater were considered malignant (including tumours of borderline malignancy or low malignant potential).
RESULTS: The malignancy rates of masses with scores of 2, 3, 4 and 5 were 1.9% (8/419), 12.8% (19/149), 62.6% (57/91) and 87.4% (104/119) for reader 1 and 2.1% (9/424), 13.6% (20/147), 67.6% (71/105) and 86.3% (88/102) for reader 2, respectively. The areas under the ROC curves for the differentiation of benign and malignant masses were 0.929 and 0.923, respectively; the sensitivity, specificity and accuracy of diagnosis were 85.6% (161/188), 91.7% (541/590), and 90.2% (702/778) for reader 1 and 84.6% (159/188), 91.9% (542/590), and 90.1% (701/778) for reader 2, respectively. Tumours of borderline malignancy or low malignant potential had a higher rate of misclassification (46.1%) than other malignant tumours (6-7.4%).
CONCLUSION: The ADNEX MR SCORING system was highly accurate in differentiating benign and malignant adnexal masses, although it may be less accurate for tumours of borderline malignancy or low malignant potential.
引用
- Sasaguri K, Yamaguchi K, Nakazono T, et al. External validation of ADNEX MR SCORING system: a single-centre retrospective study. Clin Radiol. 2018. PMID: 30514585. doi:10.1016/j.crad.2018.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。